Read the new article “Brief recommendations on the management of adult patients with FH during the COVID-19 pandemic”
Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
Authors: Maciej Banacha,b,c,,1, Peter E. Pensond, Zlatko Frase, Michal Vrablikf, Daniel Pellag, Željko Reinerh, Seyed Mohammad Nabavii, Amirhossein Sahebkarj,k,l, Meral Kayikcioglum, Magdalena Daccordn,*,1, on behalf of the FH Europe and the International Lipid Expert Panel (ILEP)
Individuals with Familial Hypercholesterolaemia (FH) are at very high risk of cardiovascular disease, which is associated with poor outcomes from coronavirus infections. COVID-19 puts strain on healthcare systems and
may impair access to routine FH services. On behalf of the International Lipid Expert Panel (ILEP) and the European FH Patient Network (FH Europe), we present brief recommendations on the management of adultpatients with FH during the COVID-19 pandemic. We discuss the plications of COVID-19 infections for FH patients, the importance of continuing lipid-lowering therapy where possible, issues relating to safety monitoring and service delivery. We summarise the evidence for additional benefits of statins and other lipid-lowering drugs during viral infections. The recommendations do not override in any way the individual responsibility of physicians to make appropriate and accurate decisions taking into account the condition of a given patient and the doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.
Please find the article HERE.